Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19) resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2), where there is significant unmet medical need.
Epistemonikos ID: 420308244007d3bf46e026b29e7681cc1e05635f
First added on: Apr 06, 2020